Productive steps toward an antimicrobial targeting virulence

Current Opinion in Microbiology

Volumn 12, Issue 5, 2009, Pages 490-496

  Barczak, Amy K ^a   Hung, Deborah T ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 IMINO 5 ARYLIDENE THIAZOLIDINONE; 2 PYRIDONE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BPH 652; D 157070; LED 209; REP 3123; UNCLASSIFIED DRUG; VIRSTATIN; VIRULENCE FACTOR;

BACTERIUM ADHERENCE; BIOFILM; CELL COMMUNICATION; DRUG TARGETING; ESSENTIAL GENE; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; SECRETION; VIRULENCE;

ANTI-BACTERIAL AGENTS; BIOFILMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; VIRULENCE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 70349756864     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2009.06.012     Document Type: Review

References (49)

1. Miller L.G., and Kaplan S.L. Staphylococcus aureus: A Community Pathogen. Infect Dis Clinics N Am 23 (2009) 35
2. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., and Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. Bmc Infect Dis 5 (2005) 7
3. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 22 (2009) 167-173
4. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discover 6 (2007) 29-40
5. Heath R.J., White S.W., and Rock C.O. Lipid biosynthesis as a target for antibacterial agents. Progress Lipid Res 40 (2001) 467-497
6. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y.S., Cummings R., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006) 358-361
7. Wang J., Kodali S., Lee S.H., Galgoci A., Painter R., Dorso K., Racine F., Motyl M., Hernandez L., Tinney E., et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci U S A 104 (2007) 7612-7616
8. Brinster S., Lamberet G., Staels B., Trieu-Cuot P., Gruss A., and Poyart C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458 (2009) U83-U85
9. Munoz-Elias E.J., and McKinney J.D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11 (2005) 638-644
10. Henderson D.P., and Payne S.M. Vibrio-cholerae iron transport-systems - roles of heme and siderophore iron transport in virulence and identification of a gene associated with multiple iron transport-systems. Infect Immun 62 (1994) 5120-5125
11. Galan J.E., and Collmer A. Type III secretion machines: Bacterial devices for protein delivery into host cells. Science 284 (1999) 1322-1328
12. Bryk R., Lima C.D., Erdjument-Bromage H., Tempst P., and Nathan C. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295 (2002) 1073-1077
13. Clatworthy A.E., Pierson E., and Hung D.T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3 (2007) 541-548
14. Geske G.D., O'Neill J.C., and Blackwell H.E. Expanding dialogues: from natural autoinducers to non-natural analogues that modulate quorum sensing in Gram-negative bacteria. Chem Soc Rev 37 (2008) 1432-1447
15. Cegelski L., Marshall G.R., Eldridge G.R., and Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6 (2008) 17-27
16. Hett E.C., and Hung D.T. Chemical Biology Approaches to Host-Pathogen Interactions (2008), Wiley Encyclopedia of Chemical Biology
17. Kim C., Kim J., Park H.Y., Park H.J., Lee J.H., Kim C.K., and Yoon J. Furanone derivatives as quorum-sensing antagonists of Pseudomonas aeruginosa. Appl Microbiol Biotechnol 80 (2008) 37-47
18. Janssens J.C.A., Steenackers H., Robijns S., Gellens E., Levin J., Zhao H., Hermans K., De Coster D., Verhoeven T.L., Marchal K., et al. Brominated furanones inhibit biofilm formation by Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 74 (2008) 6639-6648
19. Estephane J., Dauvergne J., Soulere L., Reverchon S., Queneau Y., and Doutheau A. N-acyl-3-amino-5H-furanone derivatives as new inhibitors of LuxR-dependent quorum sensing: Synthesis, biological evaluation and binding mode study. Bioorg Med Chem Lett 18 (2008) 4321-4324
20. Geske G.D., Mattmann M.E., and Blackwell H.E. Evaluation of a focused library of N-aryl L-homoserine lactones reveals a new set of potent quorum sensing modulators. Bioorg Med Chem Lett 18 (2008) 5978-5981
21. Wang W.Z., Morohoshi T., Ikeda T., and Chen L. Inhibition of Lux quorum-sensing system by synthetic N-acyl-L-homoserine lactone analogous. Acta Biochim Biophys Sin 40 (2008) 1023-1028
22. Morohoshi T., Shiono T., Takidouchi K., Kato M., Kato N., Kato J., and Ikeda T. Inhibition of quorum sensing in Serratia marcescens AS-1 by synthetic analogs of N-acylhomoserine lactone. Appl Environ Microbiol 73 (2007) 6339-6344
23. Park J., Kaufmann G.F., Bowen J.P., Arbiser J.L., and Janda K.D. Solenopsin A, a venom alkaloid from the fire ant Solenopsis invicta, inhibits quorum-sensing signaling in Pseudomonas aeruginosa. J Infect Dis 198 (2008) 1198-1201
24. Lesic B., Lepine F., Deziel E., Zhang J.W., Zhang Q.H., Padfield K., Castonguay M.H., Milot S., Stachel S., Tzika A.A., et al. Inhibitors of pathogen intercellular signals as selective anti-infective compounds. Plos Pathog 3 (2007) 1229-1239. Identification of anthranilic acid analogues that give in vivo protection against Pseudomonas aeruginosa infection by blocking quorum sensing. Analogues may also have broader spectrum activity, as shown by activity against Burkholdaria species.
25. Rasko D.A., Moreira C.G., Li D.R., Reading N.C., Ritchie J.M., Waldor M.K., Williams N., Taussig R., Wei S.G., Roth M., et al. Targeting QseC signaling and virulence for antibiotic development. Science 321 (2008) 1078-1080. High-throughput screen discovery of a histidine kinase inhibitor that blocks quorum sensing in multiple Gram-negative bacteria. In vivo efficacy is shown in mouse models of infection with Francisella tularensis and Salmonella typhimurium.
26. Keyser P., Elofsson M., Rosell S., and Wolf-Watz H. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Inter Med 264 (2008) 17-29
27. Felise H.B., Nguyen H.V., Pfuetzner R.A., Barry K.C., Jackson S.R., Blanc M.P., Bronstein P.A., Kline T., and Miller S.I. An Inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4 (2008) 325-336. Identification of a broad-spectrum inhibitor of Gram-negative bacterial secretion with evidence of in vivo effect against plant pathogen Pseudomonas syringae.
28. Wolf K., Betts H.J., Chellas-Gery B., Hower S., Linton C.N., and Fields K.A. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 61 (2006) 1543-1555
29. Dobrindt U., and Hacker J. Targeting virulence traits: potential strategies to combat extraintestinal pathogenic E. coli infections. Curr Opin Microbiol 11 (2008) 409-413
30. Aberg V., Das P., Chorell E., Hedenstrom M., Pinkner J.S., Hultgren S.J., and Almqvist F. Carboxylic acid isosteres improve the activity of ring-fused 2-pyridones that inhibit pilus biogenesis in E. coli. Bioorg Med Chem Lett 18 (2008) 3536-3540
31. Aberg V., Fallman E., Axner O., Uhlin B.E., Hultgren S.J., and Almqvist F. Pilicides regulate pili expression in E. coli without affecting the functional properties of the pilus rod. Mol Biosyst 3 (2007) 214-218
32. Pemberton N., Pinkner J.S., Edvinsson S., Hultgren S.J., and Almqvist F. Synthesis and evaluation of dihydroimidazolo and dihydrooxazolo ring-fused 2-pyridones - targeting pilus biogenesis in uropathogenic bacteria. Tetrahedron 64 (2008) 9368-9376
33. Wellens A., Garofalo C., Nguyen H., Van Gerven N., Slattegard R., Hernalsteens J.P., Wyns L., Oscarson S., De Greve H., Hultgren S., et al. Intervening with urinary tract infections using anti-adhesivesbased on the crystal structure of the FimH-soligomannose-3 complex. PLoS One 3 (2008) e2040
34. Touaibia M., and Roy R. Glycodendrimers as anti-adhesion drugs against type 1 fimbriated E. coli uropathogenic infections. Mini-Rev Med Chem 7 (2007) 1270-1283
35. Suree N., Jung M.E., and Clubb R.T. Recent advances towards new anti-infective agents that inhibit cell surface protein anchoring in Staphylococcus aureus and other Gram-positive pathogens. Mini-Rev Med Chem 7 (2007) 991-1000
36. Maresso A.W., and Schneewind O. Sortase as a target of anti-infective therapy. Pharmacol Rev 60 (2008) 128-141
37. Chenna B.C., Shinkre B.A., King J.R., Lucius A.L., Narayana S.V.L., and Velu S.E. Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A. Bioorg Med Chem Lett 18 (2008) 380-385
38. Kudryavtsev K.V., Bentley M.L., and McCafferty D.G. Probing of the cis-5-phenyl proline scaffold as a platform for the synthesis of mechanism-based inhibitors of the Staphylococcus aureus sortase SrtA isoform. Bioorg Med Chem 17 (2009) 2886-2893
39. Jang K.H., Chung S.C., Shin J., Lee S.H., Kim T.I., Lee H.S., and Oh K.B. Aaptamines as sortase A inhibitors from the tropical sponge Aaptos aaptos. Bioorg Med Chem Lett 17 (2007) 5366-5369
40. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5 (2007) 48-56
41. Junker L.M., and Clardy J. High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development. Antimicrob Agents Chemother 51 (2007) 3582-3590
42. Huigens R.W., Rogers S.A., Steinhauer A.T., and Melander C. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7 (2009) 794-802
43. Hung D.T., Shakhnovich E.A., Pierson E., and Mekalanos J.J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310 (2005) 670-674. Describes a small molecule inhibitor of cholera toxin transcription with efficacy in a mouse model of infection.
44. Ochsner U.A., Bell S.J., O'Leary A.L., Hoang T., Stone K.C., Young C.L., Critchley I.A., and Janjic N. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 63 (2009) 964-971
45. Loo V.G. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality (vol 353, pp. 2442, 2005). N Engl J Med 354 (2006) 2200-12200
46. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Felcetto T., Michael B.F., Bansal A., Cummings R.T., et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A 102 (2005) 7958-7963
47. Xiong Y.S., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Tang W., Bansal A., Cummings R.T., Cunningham B.R., Friedlander A.M., et al. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett 16 (2006) 964-968
48. Liu C.I., Liu G.Y., Song Y.C., Yin F.L., Hensler M.E., Jeng W.Y., Nizet V., Wang A.H.J., and Oldfield E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319 (2008) 1391-1394. Discovery of an antivirulence compound that targets Staphylococcus aureus protections from the host immune system is shown to have a protective effect in vivo.
49. Bryk R., Gold B., Venugopal A., Singh J., Samy R., Pupek K., Cao H., Popescu C., Gurney M., Hotha S., et al. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3 (2008) 137-145. Includes identification of a molecule that blocks mycobacterial protections from the host immune system. Efficacy is shown in a mouse model of infection.